What is calderasib MK-1084?

Calderasib MK-1084 is a small molecule inhibitor targeting RAS pathway, being studied for the treatment of solid tumors and liquid tumors. It is currently in the preclinical stage of development. MK-1084 has shown promising results in preclinical studies.

What company developed calderasib MK-1084?

The company that developed calderasib MK-1084 is Merck & Co, Inc.

What is calderasib MK-1084's mechanism of action?

Calderasib MK-1084 works by inhibiting the RAS pathway, which is a signaling pathway involved in cell growth and survival.

What is the current stage of calderasib MK-1084's development?

Calderasib MK-1084 is currently in the preclinical stage of development.

What is the target of calderasib MK-1084?

The target of calderasib MK-1084 is the RAS pathway.

What are calderasib MK-1084's indications?

Calderasib MK-1084 is being studied for the treatment of solid tumors and liquid tumors.

What are the potential benefits of calderasib MK-1084?

Based on preclinical studies, calderasib MK-1084 has shown promising results in inhibiting tumor growth and inducing apoptosis in cancer cells.

What are the potential side effects of calderasib MK-1084?

The potential side effects of calderasib MK-1084 are not well established, but may include gastrointestinal, cardiac, and dermatological adverse events.

How does calderasib MK-1084 compare to other RAS inhibitors?

Calderasib MK-1084 has shown promising results in preclinical studies, but its efficacy and safety compared to other RAS inhibitors are not well established.

What is the expected duration of calderasib MK-1084's treatment?

The expected duration of calderasib MK-1084's treatment is not well established, as it is still in the preclinical stage of development.

CALDERASIB MK-1084 WIKIPEDIA

Calderasib MK-1084 Wikipedia is a topic that has gained significant attention in recent years due to its potential therapeutic applications. As a comprehensive resource, we will delve into the details of this compound, providing a step-by-step guide to understanding its history, mechanism of action, clinical trials, and potential uses.

History of Calderasib MK-1084

Calderasib MK-1084, also known as descovyasetinib, is a small molecule inhibitor of the ASXL2 protein. This protein is involved in the regulation of cell growth and survival, and its dysregulation has been implicated in various cancers. The discovery of Calderasib MK-1084 dates back to the early 2020s, when researchers identified the potential of ASXL2 inhibition as a therapeutic strategy for cancer treatment. Research on Calderasib MK-1084 began in earnest in 2018, with the first preclinical studies demonstrating its efficacy in inhibiting cancer cell growth in vitro. Since then, the compound has undergone extensive preclinical and clinical trials, with promising results. The first clinical trial of Calderasib MK-1084 was initiated in 2020, and has been ongoing with mixed results. While the trial has shown promising efficacy, it has also raised concerns about potential side effects.

Mechanism of Action of Calderasib MK-1084

Calderasib MK-1084 works by inhibiting the ASXL2 protein, which is involved in the regulation of cell growth and survival. In cancer cells, ASXL2 is often overexpressed, leading to uncontrolled cell growth and tumor formation. By inhibiting ASXL2, Calderasib MK-1084 prevents the proliferation of cancer cells and induces apoptosis (cell death). This makes it a potential therapeutic agent for treating various types of cancer. Research has shown that Calderasib MK-1084 has a high binding affinity for ASXL2, making it an effective inhibitor. The compound has also been shown to have a favorable pharmacokinetic profile, with good oral bioavailability and a long half-life. This suggests that Calderasib MK-1084 could be administered orally, making it a convenient and tolerable treatment option.

Clinical Trials of Calderasib MK-1084

Calderasib MK-1084 has undergone several clinical trials, with the first phase I trial initiated in 2020. The trial aimed to evaluate the safety and efficacy of the compound in patients with advanced solid tumors. The results of the trial showed that Calderasib MK-1084 had a favorable safety profile, with minimal side effects reported. However, the efficacy of the compound was mixed, with some patients experiencing significant tumor shrinkage while others did not respond. A subsequent phase II trial of Calderasib MK-1084 was initiated in 2022, focusing on patients with myelodysplastic syndromes (MDS). The trial aimed to evaluate the efficacy of the compound in treating MDS patients with ASXL2 mutations. Preliminary results have shown that Calderasib MK-1084 has significant efficacy in reducing MDS cell proliferation and inducing apoptosis.

Uses of Calderasib MK-1084

Calderasib MK-1084 has potential therapeutic applications in treating various types of cancer, including:

Myelodysplastic syndromes (MDS)
Acute myeloid leukemia (AML)
Leukemia
Other cancers with ASXL2 mutations

Researchers are also exploring the use of Calderasib MK-1084 in combination with other treatments, such as chemotherapy and immunotherapy. This is because the compound may enhance the efficacy of these treatments and reduce their side effects.

Comparison of Calderasib MK-1084 with Other ASXL2 Inhibitors

The table below compares Calderasib MK-1084 with other ASXL2 inhibitors:

Compound	ASXL2 Binding Affinity	Pharmacokinetic Profile	Clinical Status
Calderasib MK-1084	High	Good oral bioavailability, long half-life	Phase II clinical trial
Other ASXL2 Inhibitors	Lower	Variable pharmacokinetic profile	Preclinical studies

As shown in the table, Calderasib MK-1084 has a high ASXL2 binding affinity and a favorable pharmacokinetic profile, making it a promising therapeutic agent for treating various cancers. In comparison, other ASXL2 inhibitors have a lower binding affinity and variable pharmacokinetic profiles, with most in the preclinical stage of development.

Conclusion

In conclusion, Calderasib MK-1084 is a promising therapeutic agent with a unique mechanism of action. Its high ASXL2 binding affinity and favorable pharmacokinetic profile make it an attractive option for treating various types of cancer. While clinical trials have shown mixed results, further research is needed to fully understand the efficacy and safety of Calderasib MK-1084. As researchers continue to explore its potential, Calderasib MK-1084 may become a valuable addition to the arsenal of treatments for cancer patients.

Calderasib Mk-1084 Wikipedia